Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Shuang LiuXiaoZhong WangYeZhong ZhuangShouMin BaiXiaoJun WuYiJing YeHuiLong LuoHaiNa YuQiaoXuan WangHui ChangZhiFan ZengPeiQiang CaiZhiZhong PanYuan-Hong GaoGong ChenWei-Wei XiaoPublished in: Cancer medicine (2023)
The TESS trial aims to explore a new TNT strategy, which is expected to increase the rate of cCR and sphincter preservation rate. This study will provide new options and evidence for a new sandwich TNT strategy in patients with distal LARC.